Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI – Get Rating) major shareholder Global Strategic Fund I. Venbio sold 37,500 shares of the company’s stock in a transaction that occurred on Wednesday, May 4th. The shares were sold at an average price of $10.37, for a total value of $388,875.00. Following the completion of the transaction, the insider now directly owns 2,535,158 shares in the company, valued at approximately $26,289,588.46. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Shares of CMPI stock opened at $10.37 on Thursday. Checkmate Pharmaceuticals, Inc. has a fifty-two week low of $2.00 and a fifty-two week high of $10.48. The stock’s fifty day moving average price is $4.81 and its two-hundred day moving average price is $3.79.
Checkmate Pharmaceuticals (NASDAQ:CMPI – Get Rating) last released its quarterly earnings data on Tuesday, March 29th. The company reported ($0.62) earnings per share for the quarter. On average, analysts forecast that Checkmate Pharmaceuticals, Inc. will post -3.14 earnings per share for the current year.
Several equities analysts have recently commented on CMPI shares. BTIG Research downgraded Checkmate Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Wednesday, April 20th. Zacks Investment Research upgraded Checkmate Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday.
About Checkmate Pharmaceuticals (Get Rating)
Checkmate Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma.
- Get a free copy of the StockNews.com research report on Checkmate Pharmaceuticals (CMPI)
- World Wresting Entertainment Stock is Hulking Up
- High-Yield Weyco Group Returns To Reasonable Levels
- MarketBeat Podcast: Alternative Investing Strategies Despite Market Volatility
- Limelight Networks Stock is a Speculative Turnaround Opportunity
- The Selloff In SiteOne Landscape Supply Is Overextended
Receive News & Ratings for Checkmate Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkmate Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.